| Market Capitalization (Millions $) |
25,427 |
| Shares
Outstanding (Millions) |
243 |
| Employees |
3,500 |
| Revenues (TTM) (Millions $) |
4,277 |
| Net Income (TTM) (Millions $) |
1,042 |
| Cash Flow (TTM) (Millions $) |
15,540 |
| Capital Exp. (TTM) (Millions $) |
279 |
Biontech Se
Biontech SE is a German biotechnology company that focuses on developing immunotherapies for cancer and other medical conditions.
Founded in 2008 by husband-and-wife team Ugur Sahin and 'zlem T'reci, the company has its headquarters in Mainz, Germany, and operates research and development facilities in both the United States and Germany.
Biontech is primarily focused on the development of mRNA-based therapeutics, which involve the use of messenger RNA molecules to instruct cells to produce specific proteins or antibody molecules that can help fight various diseases.
As of 2021, Biontech is perhaps best known for its collaboration with Pfizer on the development of the BNT162b2 COVID-19 vaccine, which has been authorized for emergency use by regulatory agencies around the world.
The vaccine is based on mRNA technology, and has demonstrated high efficacy in clinical trials.
Biontech and Pfizer have also collaborated on the development of other potential mRNA-based therapies, including treatments for influenza and other infectious diseases.
Aside from its work on mRNA therapeutics, Biontech is also engaged in research into various types of cancer immunotherapies, including CAR-T cell therapies and checkpoint inhibitors.
The company has a number of clinical trials underway for these types of treatments, and has signed collaborations and licensing deals with a range of pharmaceutical companies.
Overall, Biontech is one of the leading biotechnology firms in Germany, with a reputation for innovation and a strong track record of success in developing cutting-edge therapies for a range of medical conditions.
The company employs hundreds of scientists and researchers, and is well-positioned to continue driving innovation in the field of immunotherapy and beyond.
Company Address: An der Goldgrube 12 Mainz 0
Company Phone Number: 6131-9084-0 Stock Exchange / Ticker: NASDAQ BNTX
|
0.26% 